Wechselwirkungen · Aripiprazole Sandoz
Aripiprazole Sandoz 5 mg tablets Aripiprazole Sandoz 10 mg tablets Aripiprazole Sandoz 15 mg tablets Aripiprazole Sandoz 20 mg tablets Aripiprazole Sandoz 30 mg tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-133646 · Präparat HOS-097480
Quinidine and other CYP2D6 inhibitors In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107%, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32% and 47%, respectively. Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) quinidine (HOS-085593) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-21T11:00:00Z · SHA-256 327ef54b8c9603e9d2d852929d852cc6b552a07adfbdb4be62ec8d86171c0375 · Passage 3710b4910f9b9b5e88c7dc04d1064b5090cc7500e07fa3cb4fd3a98e459169b4 · Zeichen 909–1518 im Abschnitt